$LPTN (Lpath Inc.)

$LPTN {{ '2016-09-09T11:09:16+0000' | timeago}} • Announcement

The Apollo security holders are expected to own approx. 95.8% of the combined company and the $LPTN security holders are expected to own approx. 4.2% of the combined company subject to adjustments. Upon closing of the transaction $LPTN will be renamed Apollo Endosurgery, Inc. and will be traded under a new trading symbol on NASDAQ.

$AGN {{ '2018-01-09T15:46:35+0000' | timeago}} • Announcement

$AGN, which announced its plan to give pink slips to 1,000 of its employees and cut down 400 open positions earlier this year, provided FY18 financial outlook. In 2018, Allergan plans to sell its remaining position of 10% stake in $TEVA through Forward Sale Agreements and/or open market sales.

$CELG {{ '2018-01-08T19:25:23+0000' | timeago}} • Announcement

$CELG announced preliminary results for 4Q17 and FY17. Celgene also provided the outlook for FY18 and reaffirmed FY20 guidance. The company is expected to finalize these results when it announces the earnings results on Jan. 25, 2018.

$CELG {{ '2018-01-08T14:00:46+0000' | timeago}} • Announcement

$CELG agreed to acquire start-up firm Impact Biomedicines for an upfront payment of $1.1Bil. Under the deal terms, Celgene will further pay up to $1.25Bil on Impact's cancer drug Fedratinib getting FDA's approvals. If the global annual net sales of the drug exceed $5Bil, Celgene will pay a maximum of $4.5Bil. The deal is expected to close in 1Q18.

$AGN {{ '2017-12-26T12:22:55+0000' | timeago}} • Announcement

$AGN said that the Federal Circuit confirmed that a proposed generic version of Combigan eye drug from Sandoz, a unit of $NVS, did not infringe Allergan's two patents. The Federal Circuit also reversed the district court's decision that Sandoz's proposed generic product infringes Allergan's 3rd patent. Allergan plans to file for rehearing within 30 days.

$CELG {{ '2017-12-22T14:11:59+0000' | timeago}} • Announcement

$CELG's cancer drug Revlimid fails to meet the endpoint in the first Phase 3 trial. Celgene said that additional analyses are ongoing and it would present the complete analyzed data in a future medical conference. Revlimid contributed 63% of Celgene's revenue in their recently ended third quarter.

$AGN {{ '2017-12-21T14:38:43+0000' | timeago}} • Announcement

$AGN and its partner $PRTK announced that FDA accepted to review Seysara, an investigational drug for treating acne. Allergan, which has the U.S. rights of developing and marketing Seysara, expects FDA to take action on this in 2H18. Paratek retains the non-U.S. rights. In March 2017, Allergan announced positive results from Seysara Phase 3 trials.

$ABBV {{ '2017-12-21T13:23:43+0000' | timeago}} • Announcement

$ABBV announced positive top-line results from the Phase 3 SELECT-MONOTHERAPY clinical trial. Upadacitinib is not approved by regulatory authorities and its safety and efficacy have not been established.

$AGN {{ '2017-12-18T22:26:29+0000' | timeago}} • Announcement

Robert Stewart, COO of $AGN will resign from his role. He has been named as the CEO of the newly formed Amneal Pharmaceuticals, effective Jan. 25, 2018. Following Rob's departure, Wayne Swanton, SVP, Global Operations has been promoted as EVP, Global Operations of Allergan.

$AGN {{ '2017-12-18T22:14:14+0000' | timeago}} • Announcement

$AGN and its development partner Gedeon Richter Plc reported positive results from phase 3 study of cariprazine, which is used to treat the bipolar depression. Allergan plans to file the New Drug Application to the FDA in 2H18.

$IPXL {{ '2017-12-18T13:05:53+0000' | timeago}} • Announcement

Amneal Pharmaceuticals LLC and $IPXL said Robert Stewart will join Amneal as President, effective Jan. 25, 2018. Stewart most recently served as COO of $AGN. After completion of combination of Amneal and $IPXL, Stewart will become President and CEO of the combined company, to be named Amneal Pharmaceuticals Inc., and will become a BoD member.

$ABT {{ '2017-12-15T16:46:17+0000' | timeago}} • Announcement

$ABT increased the company's quarterly common dividend to $0.28 per share from $0.265 per share.  The cash dividend is payable Feb. 15, 2018, to shareholders of record at the close of business on Jan. 12, 2018.

$AGN {{ '2017-12-12T19:58:45+0000' | timeago}} • Announcement

$AGN gets FDA clearance for the CoolSculpting, a treatment to improve the appearance of lax tissue in double chin. Allergan got this CoolSculpting technology by acquiring Zeltiq Aesthetics in Feb. 2017 for $2.4Bil. Allergan added that in an 18-week study, 77% of patients showed improved appearance in their lax tissue.

$AGN {{ '2017-12-12T19:07:05+0000' | timeago}} • Announcement

$AGN enters into a buyout deal with $RPRX through a cash tender offer of $0.67 per share, representing a 43% premium of Repros Therapeutics’ Dec. 11th closing price ($0.47). Allergan's subsidiary will acquire Repros, which focuses on developing the drugs for male and female reproductive disorders. The deal is expected to close in 1Q18.

$LLY {{ '2017-12-11T17:36:13+0000' | timeago}} • Announcement

FDA accepts to review $LLY's Galcanezumab, an injectionable drug for the treatment of migraine. Rivals $NVS and $AMGN already filed their migraine drug with FDA in July 2017, while $TEVA is also expected to join the race. Lilly's pain portfolio also includes Tanezumab, developed in partnership with $PFE, for the treatment of osteoarthritis.

$SGEN {{ '2017-12-11T16:30:10+0000' | timeago}} • Announcement

$SGEN and $BMY highlighted updated interim results from an ongoing phase 1/2 clinical trial evaluating the combination of Adcetris (brentuximab vedotin) and Opdivo (nivolumab) in relapsed or refractory classical Hodgkin lymphoma (HL).

$CELG {{ '2017-12-11T14:27:28+0000' | timeago}} • Announcement

$CELG and $JUNO report additional data from the TRANSCEND study. Celgene added that the results of this study show the potential for the CAR T therapy, a therapy to treat cancers. Application filing is expected to be completed in 2H18, with approval as early as the end of 2018. In June 2015, Celgene partnered with Juno Therapeutics by paying $1Bil.

$CELG {{ '2017-12-11T13:33:44+0000' | timeago}} • Announcement

$CELG and its partner $BLUE announce results of Phase I study of bb2121, a therapy that is jointly developed by both the companies for treating blood cancer. Of the 18 patients enrolled for this trial, 56% achieved complete response and only one patient (6%) didn't respond to the treatment.

$AGN {{ '2017-12-05T18:08:04+0000' | timeago}} • Announcement

Revance Therapeutics reported positive data for RT002, an injectable drug which would treat glabellar or frown lines. With positive results from the two Phase 3 trials, $AGN's rival plans to complete the third Phase 3 trial in 2H18 and file for FDA approval in 1H19, and introduce the competitive drug for Allergan's Botox in the U.S. in 2020.

$ABBV {{ '2017-12-04T15:31:15+0000' | timeago}} • Announcement

$ABBV announced that Risankizumab met all co-primary and ranked secondary endpoints in Phase 3 study. Risankizumab is used in the treatment of patients with moderate to severe plaque psoriasis.

$ENTA {{ '2017-11-20T21:52:37+0000' | timeago}} • Announcement

Biotech company $ENTA swung to 4Q17 profit on higher revenue, driven by milestone payments totaling $65MM received following $ABBV's U.S. approval of MAVYRET and EU approval of MAVIRET. Net income was $36.5MM or $1.86 per share in the quarter compared to a net loss of $1.8MM, or $0.09 loss per share a year earlier. Revenue jumped to $75.9MM.

Recent Transcripts

ONVO (Organovo Holdings, Inc.)
Thursday, November 9 2017 - 10:00pm
SGMO (Sangamo Biosciences Inc.)
Thursday, November 9 2017 - 10:00pm
BTX (BioTime, Inc.)
Thursday, November 9 2017 - 9:30pm
RGEN (Repligen Corporation)
Thursday, November 9 2017 - 1:30pm
VRML (Vermillion, Inc.)
Wednesday, November 8 2017 - 9:30pm
ATRS (Antares Pharma Inc.)
Tuesday, November 7 2017 - 1:30pm
AGN (Allergan plc)
Wednesday, November 1 2017 - 12:30pm
AMRN (Amarin Corporation plc)
Wednesday, November 1 2017 - 12:00pm
TECH (Bio-Techne Corp.)
Tuesday, October 31 2017 - 1:00pm
ABBV (AbbVie Inc.)
Friday, October 27 2017 - 1:00pm
SGEN (Seattle Genetics, Inc.)
Thursday, October 26 2017 - 8:30pm
CELG (Celgene Corporation)
Thursday, October 26 2017 - 1:00pm
NVS (Novartis AG)
Tuesday, October 24 2017 - 12:00pm
ABT (Abbott Laboratories)
Wednesday, October 18 2017 - 1:00pm
SGMO (Sangamo Biosciences Inc.)
Wednesday, August 9 2017 - 9:00pm
ONVO (Organovo Holdings, Inc.)
Wednesday, August 9 2017 - 9:00pm
VRML (Vermillion, Inc.)
Wednesday, August 9 2017 - 8:30pm
TECH (Bio-Techne Corp.)
Tuesday, August 8 2017 - 1:00pm
ATRS (Antares Pharma Inc.)
Tuesday, August 8 2017 - 12:30pm
RGEN (Repligen Corporation)
Thursday, August 3 2017 - 12:31pm

AlphaGraphics you may like